A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-05-12 / J Transl Med 2017 05;15(1):104Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2017-04-27 / Sci Rep 2017 04;7(1):1217Dendritic cell based vaccination strategy: an evolving paradigm
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-235Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-1909Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
/in Brain Tumors in Children, Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-04-12 / Onco Targets Ther 2017;10:2097-2106Tumor Vaccines for Malignant Gliomas
/in Glioblastoma, International Publications /von 2017-04-01 / Neurotherapeutics 2017 04;14(2):345-357Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
/in Checkpoint-Inhibitors, Glioblastoma, International Publications /von 2017-04-01 / Cancer Control 2017 Apr;24(2):180-186Immune and viral therapies for malignant primary brain tumors
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474History and current state of immunotherapy in glioma and brain metastasis
/in Glioblastoma, International Publications /von 2017-02-01 / Ther Adv Med Oncol 2017 May;9(5):347-368
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution